Skip to content

Clinical study of Tanshinone II A protecting blood brain barrier in acute ischemia stroke patient with recombinant tissue plasminogen activator (rt-PA) treatment

Clinical study of Tanshinone II A protecting blood brain barrier in acute ischemia stroke patient with recombinant tissue plasminogen activator (rt-PA) treatment

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-14004659
Enrollment
Unknown
Registered
2014-09-21
Start date
2014-05-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemia stroke

Interventions

Sponsors

Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)the age of 18-80 years of age hospitalized patients;2)patients are diagnosed to acute ischemic infarction;3)meet thrombolysis criterion and agree to rt-PA treatment;4)Neurological deficit score (NIHSS) score of 4-25points; 5)Patients agree to sign clinical use informed consent;6)cooperate to medical history collection and follow-up.

Exclusion criteria

Exclusion criteria: 1)CT examinations indicate cerebral bleeding; 2) not meet thrombolysis criterion and agree to rt-PA treatment; 3)Associated pneumonia or other serious infections; 4) patients suffer from cardiac insufficiency, chronic liver disease(A/G inversion), ALT rising up to 1.5 times of normal value,blood creatinine elevating higher than 1.5 times of normal value or other serious systemic or organ organic diseases; allergic constitution, allergic history to various drugs; 5)Serum HIV, syphilis antibody positive, hepatitis b or hepatitis c patients;6)severe mental disorders, or existing other conditions who can not cooperate;7)Occurred malignancy or ongoing anti-tumor treatment; 8)pregnancy or lactating women; 9)participate in any other interventional clinical research in three months after obtaining informed consent, or is participating in other intervention clinical research; 10)other situation not suitable for clinical study of patients by the doctor.

Design outcomes

Primary

MeasureTime frame
NIHSS score;permeability surface(PS);mRS score;mean transit time(MTT;

Countries

China

Contacts

Public ContactYUN XU
xuyun20042001@aliyun.com+86 025 83105208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026